The Effect of Prophylactic Treatment by Cetirizine Hydrochloride in Patients with Japanese Cedar Pollinosis.

Takagi, Shigeru; Nakamura, Yoshihisa; Suzuki, Motohiko; Ito, Hirotaka; Murakami, Shingo; Nishimura, Jo; Ueta, Yasuhiro

doi:10.5631/jibirin.93.879

Cited by 2 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After the full-text screening, 9 RCTs that compared the efficacy of treatment before and after the commencement of pollen dispersal were finally selected for inclusion in the meta-analysis. 42 43 44 45 46 47 48 49 50 The studies in the analysis included 7 for Japanese cedar, 43 44 46 50 1 for cypress, 42 and 1 for birch. 45 Six studies for antihistamine, 45 46 47 48 49 50 2 for LTRA, 42 44 and 1 for INCS 43 were evaluated.…”

Section: Key Questions and Recommendationsmentioning

confidence: 99%

“… 42 43 44 45 46 47 48 49 50 The studies in the analysis included 7 for Japanese cedar, 43 44 46 50 1 for cypress, 42 and 1 for birch. 45 Six studies for antihistamine, 45 46 47 48 49 50 2 for LTRA, 42 44 and 1 for INCS 43 were evaluated. In general, the included studies had a high risk of bias.…”

Section: Key Questions and Recommendationsmentioning

confidence: 99%

“…Six studies described adverse events. 43 44 45 46 49 50 One study reported no adverse event with INCS use. 43 A study of LTRA reported sleepiness, but did not specify whether this was in the pretreated or non-pretreated group.…”

Section: Key Questions and Recommendationsmentioning

confidence: 99%

“…44 Somnolence caused by antihistamines was reported in both pre- and post-treated groups. 45 46 49 50 According to the results of a meta-analysis that compared somnolence with cetirizine and placebo, the risk ratio of somnolence was 2.52 (95% CI, 1.78–3.57). 51 However, the incidence of adverse events did not differ significantly between fexofenadine and placebo and between OAH/INCS and INCS in other meta-analyses.…”

Section: Key Questions and Recommendationsmentioning

confidence: 99%

See 3 more Smart Citations

KAAACI Allergic Rhinitis Guidelines: Part 1. Update in Pharmacotherapy

Yang

Lee

Kim

et al. 2023

Allergy Asthma Immunol Res

View full text Add to dashboard Cite

The prevalence of allergic rhinitis (AR) and the socioeconomic burden associated with the medical cost and quality of life (QOL) of AR have progressively increased. Therefore, practical guidelines for the appropriate management of AR need to be developed based on scientific evidence while considering the real-world environment, values, and preferences of patients and physicians. The Korean Academy of Asthma, Allergy and Clinical Immunology revised clinical guidelines of AR to address key clinical questions of the management of AR. Part 1 of the revised guideline covers the pharmacological management of patients with AR in Korea. Through a meta-analysis and systematic review, we made 4 recommendations for AR pharmacotherapy, including intranasal corticosteroid (INCS)/intranasal antihistamine (INAH) combination therapy, oral antihistamine/INCS combination therapy, leukotriene receptor antagonist treatment in AR patients with asthma, and prophylactic treatment for patients with pollen-induced AR. However, all recommendations are conditional because of the low or very low evidence of certainty. Well-designed and strictly executed randomized controlled trials are needed to measure and report appropriate outcomes.

show abstract